EUROFIBROMATOSIS Type 2 is an autosomal-dominant disease characterized by the occurrence of bilateral vestibular schwannomas and other CNS tumors. 5, 6, [11] [12] [13] The prevalence of NF2 is estimated to be one case per 35,000 persons per year, with each sex being equally affected. [6] [7] [8] This disease has been linked to a genetic defect on chromosome 22q12, where a tumor suppressor gene called merlin or schwannomin is located. 15, 19 Tumors associated with NF2 tend to occur in multiples and often recur even after treatment. 2, 9, [11] [12] [13] Administering therapies to patients with this disorder therefore poses difficult clinical problems, and planning requires consideration of patient survival rates as well as prognostically important clinical features.
The prevalence of NF2 is estimated to be one case per 35,000 persons per year, with each sex being equally affected. [6] [7] [8] This disease has been linked to a genetic defect on chromosome 22q12, where a tumor suppressor gene called merlin or schwannomin is located. 15, 19 Tumors associated with NF2 tend to occur in multiples and often recur even after treatment. 2, 9, [11] [12] [13] Administering therapies to patients with this disorder therefore poses difficult clinical problems, and planning requires consideration of patient survival rates as well as prognostically important clinical features.
In our study, we analyzed data obtained in 74 patients with bilateral vestibular schwannomas and investigated both long-term survival in those who had NF2 and factors likely to influence it.
Clinical Material and Methods
Between 1986 and 1987, a nationwide questionnaire study was organized by the Ministry of Health and Welfare of Japan to clarify the clinicopathological findings and prognosis of neurofibromatosis. 20 The senior author (J.Y.) was a member of that study. All cases were registered by neurosurgeons throughout Japan. In the survey, 283 patients with either one of the two types of neurofibromatosis were registered.
In our present study, 75 patients were selected from the 283 total based on registration reports in which bilateral vestibular schwannomas were described. Clinical data that had been submitted for these patients were reviewed retrospectively to determine survival rates following diagnosis and to clarify clinical factors affecting survival. Of the 75 patients, 71 had undergone surgical treatment at the time of registration. Clinical factors analyzed included sex, age at onset of the initial symptom, family history of neurofibromatosis, diameter of vestibular schwannomas, additional CNS tumors (other intracranial schwannomas, intracranial meningiomas, extramedullary spinal tumors, and intramedullary spinal tumors), and dermal abnormalities (subcutaneous tumors or café-au-lait spots). The current survival status of each patient was ascertained between January and March 1999 by mailing questionnaires to the patients themselves or to physicians who had treated them.
Statistical analysis of the data was performed using StatView 4.55 (Abacus Concepts, Berkeley, CA). The KaplanMeier product-limit method was used to construct curves for survival following diagnosis, and survival rates were compared using the log-rank test. Age at symptom onset was tested as a categorical variable by separating patients into groups based on onset at an age younger than 25 years and onset at an age of 25 years or older. To ascertain those factors affecting patient survival, we used univariate, weighted linear regression analysis (Cox proportional-hazards model). We also used multivariate analysis to detect factors independently affecting survival. Probability values less than 0.05 were considered to indicate statistical significance.
Characteristics of the 74 patients with NF2 are listed in Table 1. There were 40 female and 34 male patients; age at diagnosis ranged from 1 to 54 years (mean 24.1 years). The mean duration of follow up after diagnosis was 121 months (range 2-287 months). Fifteen patients were alive at the end of 1998. Thirty-one patients died during the follow-up period. Because of the retrospective nature of our analysis, we could not determine the cause of death in most patients. Twenty-eight patients were lost to follow up before 1998; their current survival status remains unknown.
Age at onset of the initial symptom ranged from younger than 1 year to 53 years, with a mean of 17.6 years. Onset age was younger than 25 years in 56 patients (76%) and 25 years or older in 18 (24%). Of 74 patients, 19 (26%) had a family history positive for neurofibromatosis.
The maximal diameter of vestibular schwannomas at diagnosis had been registered in 47 patients: measurements for both sides were available in 18 and the measurement of the larger side was available in 29. We then analyzed the measurements of the larger side of these schwannomas in 47 patients. The diameters ranged from 0.5 to 6.3 cm, with a mean of 3.3 cm. The diameter was small (Յ 2 cm) in 11 patients, medium (Ͼ 2 cm and Յ 4 cm) in 25 patients, and large (Ͼ 4 cm) in 11 patients.
In addition to vestibular schwannomas, various CNS tumors were detected on computerized tomography scanning or magnetic resonance imaging. Other cranial nerve tumors were diagnosed in 18 patients (24%); these additional tumors occurred in multiples in 12 patients (16%). Intracranial meningiomas were demonstrated in 28 patients (38%), occurring in multiples in 16 (22%). Extramedullary spinal tumors including meningiomas or schwannomas were demonstrated in 23 patients (31%), occurring in multiples in 10 (14%). Intramedullary spinal tumors were diagnosed in three patients (4%). Seventeen patients (23%) had two or more of these categories of additional CNS tumors. Subcutaneous tumors and café-au-lait spots were identified in 52 patients (70%) and 37 patients (50%), respectively.
Survival Rates in Patients With NF2
Overall 5-, 10-, and 20-year survival rates were 85, 67, and 38%, respectively (Fig. 1A) . Five-, 10-, and 20-year survival rates in patients with symptom onset at an age younger than 25 years (younger group) were 80, 60, and 28%, respectively, whereas rates in patients with symptom onset at 25 years of age or older (older group) were 100, 87, and 62%, respectively. Results of Kaplan-Meier log-rank analysis indicated that survival in the younger group was significantly worse than in the older group (p = 0.035; Table Five-, 10-, and 20-year survival rates in patients with small vestibular schwannomas at diagnosis were 83% each, whereas rates in patients with medium-sized tumors were 75, 55, and 12% and rates in patients with large tumors were 50, 50, and 30%, respectively. The rate of survival in patients with small vestibular schwannomas at diagnosis was significantly better than in patients with medium-sized tumors (p = 0.039; Table 2 and Fig. 1C) .
In univariate and multivariate analyses, a younger age (Ͻ 25 years) at symptom onset was significantly correlated with poor survival (p = 0.045 in univariate and p = 0.025 in multivariate analyses; Table 3 ). Hazard ratios (relative risk of death in younger-onset patients compared with older-onset patients) were estimated as 2.94 and 3.77 in univariate and multivariate analyses, respectively.
Discussion
Neurofibromatosis Type 2 is known as a formidable disease because of the occurrence of multiple CNS tumors that grow insidiously and recur frequently after treatment. Actual survival rates in patients with NF2 based on long-term follow-up data have not been reported, however. Evans, et al., 6 estimated that a likely median survival time for patients with NF2 was approximately 15 years following diagnosis. They also estimated that more than 40% of patients would be expected to die by the age of 50 years and that all patients would die by 70 years.
We retrospectively examined a mean of 10 years' worth of follow-up data that had been obtained in 74 patients with NF2. Using the Kaplan-Meier product-limit method, we calculated 5-, 10-, and 20-year survival rates of 85, 67, and 38%, respectively. Because of the retrospective nature of our analysis, we could not identify the cause of death in most patients. Twenty-eight patients were lost to follow up before 1998, but given that there was no distinguishing clinical feature in them, we assume that this loss did not significantly affect our analysis. To our knowledge, this is the first reported assessment of long-term survival in patients with NF2. Neurofibromatosis Type 2 was diagnosed in patients with a mean age of 24.1 years, and more than 60% of patients had died before reaching 44 years.
In a report from the Committee for Brain Tumor Registry of Japan, 5-year survival rates in patients with either schwannomas or intracranial meningiomas-representative benign brain tumors-were 97.3 or 93.3%, respectively. 4 Authors of some reports have asserted that NF2-associated vestibular schwannomas or meningiomas have a higher proliferative potential than sporadically occurring tumors, although the lesions are histologically indistinguishable. 1, 3 Even so, our results demonstrated that the prognosis of patients with NF2 was notably poor, especially considering that most CNS tumors associated with NF2 are classified as benign.
At least two distinct clinical phenotypes of NF2 have been described. 7, 13 Patients with the severe phenotype (Wishart type) usually present before the age of 25 years, have multiple CNS tumors in addition to bilateral vestibular schwannomas, and have a rapidly progressive disease course. Patients with the mild phenotype (Gardner type) usually present later in life, have a small number of tumors (often only vestibular schwannomas), and have a benign clinical course. In our analysis, the presence of additional CNS tumors or the presence of multiple categories of tumors did not affect survival. Because our data were originally obtained in 1986 and 1987, however, the finding of other CNS tumors was not frequent in this study. With recent advances in MR imaging, multiple CNS tumors can be detected in most patients with NF2. Therefore, the presence of CNS tumors in addition to vestibular schwannomas may not be a useful factor in defining Wishart and Gardner types. Regardless, the patient's age at symptom onset appears to be the main clinical factor distinguishing the two phenotypes of NF2, as confirmed by our results: 10-and 20-year survival rates in the younger-onset group (Ͻ 25 years old) were 60 and 28%, whereas those in the older-onset group (Ն 25 years) were 87 and 62%, respectively. Age at symptom onset remained a statistically significant factor in a multivariate analysis. Furthermore, our results demonstrate that patients with small vestibular schwannomas at diagnosis may have a better outcome, although tumor size in only 47 patients had been noted in the nationwide questionnaire study. Results of recent molecular genetic studies indicate that different types of mutation in the NF2 gene may be associated with differences in clinical severity; that is, severe clinical phenotypes tend to have frameshift mutations or nonsense mutations that produce a truncated protein, whereas mild phenotypes tend to have missense mutations.
14,16 A specific mutation also has been reported in pediatric patients with NF2. 10 Although we do not have any genetic information for our patients, these variations in genetic background may explain the association between the age at symptom onset and clinical severity in NF2.
Because many of our patients had already undergone surgical treatment at survey registration, survival rates calculated in our study did not represent the natural history of the disease. All patients were registered at one of the major medical institutions in Japan. Although we did not investigate treatments given following registration, our survival results presumably reflect standard treatments during the follow-up periods. Recently, favorable results were reported in treating vestibular schwannomas in patients with NF2 by performing microsurgical removal or stereotactic radiosurgery. 17, 18 These advances should decrease morbidity and possibly improve survival in patients with NF2. To compare the expected course of the disease with the outcome of recent advanced treatments, prospective studies of these new treatments are required. Our results represent baseline data concerning long-term prognosis of the disease and will help estimate the long-term effects of new treatments.
Conclusions
Long-term survival rates of patients with NF2 were shown to be unfavorable. Furthermore, patients whose initial symptoms started before the age of 25 had worse survival rates. These findings should aid in understanding the prognosis of the disease, counseling patients with NF2, considering disease management strategies, and evaluating new treatments.
